Initiating adjunct low-dose hydroxyurea therapy for stroke prevention in children with SCA during the COVID-19 pandemic
Michael R. DeBaun
Abstract
In anticipation of possible blood shortages during the current COVID-19 pandemic, DeBaun proposes rapid initiation of administration of low, fixed doses of hydroxyurea for children with sickle cell anemia (SCA) who receive regular prophylactic transfusions for stroke prevention.
Topics & Concepts
MedicinePandemicCoronavirus disease 2019 (COVID-19)Stroke (engine)Sickle cell anemiaPediatricsAnemiaAdjunctAnticipation (artificial intelligence)Intensive care medicineInternal medicineDiseaseComputer scienceArtificial intelligenceMechanical engineeringLinguisticsEngineeringInfectious disease (medical specialty)PhilosophyHemoglobinopathies and Related DisordersIron Metabolism and DisordersMyeloproliferative Neoplasms: Diagnosis and Treatment